ClinicalTrials.gg
RecruitingNCT07093606Updated Jul 30, 2025

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

An interventional study of Eltrombopag in ITP - Immune Thrombocytopenia, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Sohag University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Planned enrollment
7th of 36
100 · median 40
Started
2025
with 3 others
No phase
3 of 36
2 open now
Registered
33rd of 36
by date

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 with no phase, and was the 33rd registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

03

Conditions studied

  • ITP - Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion Criteria:

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    this group will receive Eltrombopag tabelts

    ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .

    Drug: Eltrombopag

Interventions

  • ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

06

What researchers measure

Primary outcomes

  1. •To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

    the incidence and severity of liver dysfunction in ITP patients

    Time frame: 3-6 months after receiving eltombopag

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bidika E, Fayyaz H, Salib M, Memon AN, Gowda AS, Rallabhandi B, Cancarevic I. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment. Cureus. 2020 Aug 21;12(8):e9920. doi: 10.7759/cureus.9920. PubMed 32968581 ↗
  • Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607-16. doi: 10.1182/blood-2006-10-019315. Epub 2007 Feb 8. PubMed 17289815 ↗
  • Ptushkin VV, Vinogradova OY, Pankrashkina MM, Chernikov MV, Arshanskaya EG, Tkachenko NE. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ter Arkh. 2018 Aug 17;90(7):70-76. doi: 10.26442/terarkh201890770-76. PubMed 30701925 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Jan 20, 2026
CompletionEst.
Jan 20, 2026
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093606
Lead sponsor
Sohag University
Responsible party
Peter Adel Alfy (Resident , Internal medicine, Faculty of Medicine Sohag university, Sohag University) — Principal investigator
First posted
Jul 30, 2025
Start date
Jul 14, 2025
Primary completion
Jan 20, 2026 (estimated)
Completion
Jan 20, 2026 (estimated)
Last update
Jul 30, 2025

Study contacts

Peter A Alfy, Resident
Contact
peter.adel.dola@gmail.com
01274069691
Usama M Abdelaal, Professor
Contact
01065962094

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion